Jeffrey S. Heier bought OCUL once, on Mar 15, 2019

Jeffrey S. Heier, MD is the Chief Scientific Officer at Ocular Therapeutix, Inc. (OCUL), a biopharmaceutical company focused on innovative therapies for eye diseases using sustained-release drug delivery platforms.( He recently sold shares of OCUL stock, including 3,057 shares on February 23, 2026, at approximately $9.50 per share, and 3,469 shares on November 24, 2025, at a weighted average of $12.04 per share, primarily to cover tax withholding obligations from vested restricted stock units.(

Dr. Heier serves as Director of the Vitreoretinal Service and Retina Research at Ophthalmic Consultants of Boston (OCB), a leading multi-specialty ophthalmology practice, and previously as Co-President & Medical Director from 2016-2020.( A prominent retinal researcher, he has led Phase 3 clinical trials for treatments in macular degeneration, diabetic macular edema, and retinal venous occlusive disease, earning awards like the Life Achievement Honor Award from the American Academy of Ophthalmology and induction into the Retina Hall of Fame in 2017.( He earned his MD from Boston University, completed residency at Fitzsimons Army Medical Center, vitreoretinal fellowship at OCB/Tufts, and served as a physician in the Persian Gulf War, receiving a Bronze Star.(

Written by Perplexity from public sources.